SEC Form SC 13G filed by Ashland Inc.

$ASH
Specialty Chemicals
Consumer Discretionary
Get the next $ASH alert in real time by email
SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )*

            

Ashland Inc


(Name of Issuer)

Common Stock


(Title of Class of Securities)

044186104


(CUSIP Number)

December 29, 2023


(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


CUSIP No. 044186104

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Dimensional Fund Advisors LP
30-0447847
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [ ]
(b) [X]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware Limited Partnership

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER 2,615,055 ** see Note 1 **
6. SHARED VOTING POWER 0
7. SOLE DISPOSITIVE POWER 2,658,442 ** see Note 1 **
8. SHARED DISPOSITIVE POWER 0
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,658,442 ** see Note 1 **
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[ ]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.2%
12. TYPE OF REPORTING PERSON

IA




















Item 1.
(a) Name of Issuer
Ashland Inc
(b) Address of Issuer's Principal Executive Offices
8145 Blazer Drive, Wilmington, DE 19808
Item 2.
(a) Name of Person Filing
Dimensional Fund Advisors LP
(b) Address of Principal Business Office or, if None, Residence
6300 Bee Cave Road, Building One, Austin, TX 78746
(c) Citizenship
Delaware Limited Partnership
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
044186104
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount Beneficially Owned:
2,658,442 ** see Note 1 **
(b) Percent of Class:
5.2%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote 2,615,055 ** see Note 1 **
(ii) shared power to vote or to direct the vote 0
(iii) sole power to dispose or to direct the disposition of 2,658,442 ** see Note 1 **
(iv) shared power to dispose or to direct the disposition of 0
** Note 1 ** Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. In addition, the filing of this Schedule 13G shall not be construed as an admission that the reporting person or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any other purposes than Section 13(d) of the Securities Exchange Act of 1934.
Item 5. Ownership of Five Percent or Less of Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
The Funds described in Note 1 above have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities held in their respective accounts. To the knowledge of Dimensional, the interest of any one such Fund does not exceed 5% of the class of securities. Dimensional Fund Advisors LP disclaims beneficial ownership of all such securities.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
Not Applicable
Item 8. Identification and Classification of Members of the Group.

Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
Item 9. Notice of Dissolution of Group.

Not Applicable
Item 10. Certification.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dimensional Fund Advisors LP
By: Dimensional Holdings Inc., General Partner
By: /s/ Selwyn Notelovitz
Date: February 14, 2024
Name: Selwyn Notelovitz
Title: Global Chief Compliance Officer

Get the next $ASH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ASH

DatePrice TargetRatingAnalyst
3/26/2025$68.00 → $71.00Neutral → Overweight
Analyst
3/5/2025Buy → Neutral
Seaport Research Partners
8/8/2024$90.00 → $89.00Underweight → Neutral
JP Morgan
4/11/2024$100.00 → $112.00Equal Weight → Overweight
Wells Fargo
3/14/2024$100.00 → $126.00Hold → Buy
Jefferies
3/1/2024$108.00Outperform
Wolfe Research
6/29/2023Outperform → In-line
Evercore ISI
6/26/2023$109.00 → $90.00Outperform → Market Perform
BMO Capital Markets
More analyst ratings

$ASH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Ashland to host 2025 Innovation Day for analysts and investors

    WILMINGTON, Del., March 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is hosting an Innovation Day for analysts and investors at the company's Bridgewater, New Jersey facility, Thursday, May 29, 2025. The event will showcase the enhanced capabilities and expanded applications of Ashland's scalable technology platforms. Registration is required, with options to attend via live webcast or in person. Participants will join Ashland's executive and senior technology team for an in-depth review of the latest developments and their expanding commercial opportunities. The presentations will detail how these advancements are poised to impact key markets and drive future growth. Following

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland completes sale of Avoca business to Mane

    Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem. "The Avoca business is a strong player in the fragrance fixative space, with a dedicated team and attractive manufacturing capabilities to meet customer needs," said Guillermo Novo

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland reports financial results for first quarter fiscal 20251, reiterates outlook for full-year fiscal 2025

    Sales of $405 million, down 14 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $50 million or 11 percent versus the prior-year quarter. Excluding Portfolio Optimization, sales declined 3 percent versus prior-year quarterLoss from continuing operations of $166 million, or loss of $3.51 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of                $14 million, or $0.28 per diluted shareNet loss of $165 million, or loss of $3.50 per diluted shareA

    $ASH
    Specialty Chemicals
    Consumer Discretionary

$ASH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ASH
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ASH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ASH
SEC Filings

See more

$ASH
Leadership Updates

Live Leadership Updates

See more
  • Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

    Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

    Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland Board appoints Ashish K. Kulkarni as new director

    WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors. Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization. He is the former executive vice president and chief innovation officer, GAF, former chief technology and innovation officer, Avantor and former chief technology and innovation officer, Celanese Corporation. He will serve on the Board's Environmental, Health, Safety and Quality, and Compensation Committees, effective May 6, 2024.  Prior to Celanese, Kulkarni held leadership positions at United Te

    $ASH
    Specialty Chemicals
    Consumer Discretionary

$ASH
Financials

Live finance-specific insights

See more
  • Ashland completes sale of Avoca business to Mane

    Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem. "The Avoca business is a strong player in the fragrance fixative space, with a dedicated team and attractive manufacturing capabilities to meet customer needs," said Guillermo Novo

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland reports financial results for first quarter fiscal 20251, reiterates outlook for full-year fiscal 2025

    Sales of $405 million, down 14 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $50 million or 11 percent versus the prior-year quarter. Excluding Portfolio Optimization, sales declined 3 percent versus prior-year quarterLoss from continuing operations of $166 million, or loss of $3.51 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of                $14 million, or $0.28 per diluted shareNet loss of $165 million, or loss of $3.50 per diluted shareA

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland board authorizes quarterly dividend

    WILMINGTON, Del., Jan. 20, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on March 15, 2025, to stockholders of record at the close of business on March 1, 2025. As of December 31, 2024, there were 47,182,862 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings,

    $ASH
    Specialty Chemicals
    Consumer Discretionary

$ASH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more